SI-BONE Inc (SIBN) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for SI-BONE Inc (SIBN), highlighting its current earnings forecast score and analyst ratings. It includes the average price target, high and low forecasts, and details about expected revenue and EPS for upcoming quarters. The article concludes with a peer comparison and answers frequently asked questions regarding SIBN's financial outlook.
SIBN|SI-BONE Inc|Price:16.470|Chg%:-0.240
This article provides an overview of SI-BONE Inc. (SIBN), a medical device company specializing in surgical implant systems for sacropelvic disorders. It details the company's products like iFuse and iFuse-3D, lists key executives and their shareholdings, and includes information on institutional ownership. The company's stock performance and market capitalization are also briefly mentioned.
SI-BONE to report Q2 2026 results, host conference call
SI-BONE (SIBN) is scheduled to release its second-quarter 2026 financial results on August 3, 2026. Following the release, the company will host a management conference call on the same day at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results. Interested participants can register for the webcast via the provided link.
Understanding the Setup: (SIBN) and Scalable Risk
This article analyzes Si-bone Inc. (NASDAQ: SIBN), highlighting weak near-term sentiment and a mid-channel oscillation pattern. It identifies an exceptional 57.2:1 risk-reward short setup with a 15.9% downside target versus 0.3% risk. The piece also outlines specific institutional trading strategies, including position trading, momentum breakout, and risk hedging, based on AI model analysis across multiple timeframes.
SI-BONE to report second quarter 2026 results on August 3
SI-BONE, Inc. will release its financial results for the second quarter of 2026 after the market closes on Monday, August 3, 2026. Management will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the results and provide business updates. The webcast of the call will be available for replay on the company's website for at least 90 days.
SI-BONE to report Q2 2026 results, host conference call
SI-BONE Inc. is scheduled to report its second-quarter 2026 financial results on August 3, 2026. Following the release, the company will host a management conference call on the same day at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results. Interested parties can register for the webcast via the provided link.
SI-BONE To Report Second Quarter 2026 Financial Results on August 3, 2026
SI-BONE, Inc. (Nasdaq: SIBN), a global leader in bone procedural solutions, announced it will release its second quarter 2026 financial results after market close on Monday, August 3, 2026. Management will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the results. Interested investors can register online or listen via the company's website, with an archive available for replay.
SI-BONE schedules a 4:30 p.m. ET webcast for Aug. 3
SI-BONE (Nasdaq: SIBN) announced it will release its second quarter 2026 financial results after market close on Monday, August 3, 2026. Management will host a conference call at 4:30 p.m. Eastern Time, accessible via online registration and a live audio webcast. A replay of the webcast will be available for at least 90 days on the company's investor relations website.
Truist Financial Maintains Si-Bone(SIBN.US) With Buy Rating, Raises Target Price to $21
Truist Financial has reiterated its Buy rating for Si-Bone (SIBN.US) and increased its price target to $21. This indicates a positive outlook on the company's stock performance by the financial institution.
Truist Securities Adjusts Price Target on SI-BONE to $21 From $18, Maintains Buy Rating
Truist Securities has increased its price target for SI-BONE (SIBN) shares to $21 from $18, while reiterating a Buy rating on the stock. This adjustment reflects an updated outlook from the firm regarding the medical device company. SI-BONE specializes in minimally invasive surgical implant systems for sacropelvic disorders.
Si-Bone | 4: Statement of changes in beneficial ownership of securities-Officer PISETSKY MICHAEL A.
This article is a Form 4 statement filed by Si-Bone, indicating changes in beneficial ownership of securities for officer Michael A. Pisetsky. Form 4 filings are mandatory for insiders to report their stock transactions to the SEC.
Si-Bone SVP Michael Pisetsky sells $52,375 in stock
Michael Pisetsky, SVP at SI-BONE Inc., sold 3,134 shares totaling $52,375 on July 2, 2026. These sales were made to cover tax obligations from restricted stock units, not discretionary trading. Despite the sale, Pisetsky still holds a substantial number of shares, and the company shows strong financials, including a high current ratio and revenue growth.
SI-BONE (NASDAQ: SIBN) CFO sells shares to cover RSU tax withholding
SI-BONE, Inc. (NASDAQ: SIBN) CFO Anshul Maheshwari sold 3,317 shares of common stock on July 2, 2026, in a "sell to cover" transaction to fulfill tax withholding obligations related to the vesting of restricted stock units. The sales were executed at weighted average prices of $16.7348 and $16.8017 per share. Following these transactions, Maheshwari still holds a substantial equity position of 256,560 shares, including 177,141 shares issuable from RSUs.
Form 4 Si-Bone Inc For: 6 July By Investing.com
This article from Investing.com reports on a Form 4 filing for Si-Bone Inc., detailing the filing made on July 6th. The content is brief, primarily serving as an announcement of the filing and includes a stock symbol reference for Si-Bone Inc. (SIBN).
SIBN - SI-BONE Inc Latest SEC Filings
This article provides detailed financial data and performance metrics for SI-BONE Inc (SIBN), including its latest stock price, market capitalization, earnings per share, sales, and various financial ratios. It also lists insider and institutional ownership, analyst recommendations, and recent price performance over different periods. The information is presented as a snapshot of the company's financial health and stock market activity.
Price to sales forward of SI-BONE, Inc. – NASDAQ:SIBN
The article displays the "Price to sales forward" metric for SI-BONE, Inc. (NASDAQ: SIBN). It appears to be a financial data snippet from TradingView, showing a specific period value and change percentages for this financial ratio. The broader content seems to be boilerplate information from the TradingView platform about market data, tools, and community.
Price to book forward of SI-BONE, Inc. – NASDAQ:SIBN
This article provides a brief financial overview for SI-BONE, Inc. (SIBN) on TradingView, specifically focusing on its forward price-to-book value. It indicates the market status as closed with no trades and originates from Nasdaq Stock Market data.
SI-BONE, Inc. Actuals & Estimates (NASDAQ:SIBN)
This article provides an overview of SI-BONE, Inc. (NASDAQ:SIBN) stock performance, financial data, and analyst estimates. It highlights the current stock price, market capitalization, historical highs and lows, and future price forecasts from analysts. The report also details recent earnings, revenue, net income, EBITDA, and the upcoming earnings date for the company.
SI-BONE outlines path to profitability, shares trade on Nasdaq in a volatile medtech sector
SI-BONE Inc., a medical device company specializing in minimally invasive implants for sacroiliac joint dysfunction, is working towards profitability amidst a competitive medtech landscape. Its shares trade on Nasdaq alongside larger peers, with analyst coverage focusing on revenue growth, operating margin progress, and market share in sacroiliac joint procedures. The company's business model relies on selling its proprietary iFuse implant system and associated instruments.
SI-BONE strategy focuses on differentiated sacropelvic implants, shares on Nasdaq in a competitive m
SI-BONE Inc. is a specialized medical device company listed on Nasdaq, focusing on minimally invasive sacropelvic joint fusion solutions. The company differentiates itself by concentrating on specific lower spine and pelvic conditions, offering implants and instruments for sacroiliac joint dysfunction. SI-BONE generates revenue from the sale of these products and services to hospitals and ambulatory surgery centers, relying on procedural adoption and reimbursement availability.
SIBN Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for SI-BONE Inc (SIBN), based on various technical indicators and moving averages. As of June 18, 2026, the overall consensus for SIBN is a "Strong Buy" according to Intellectia's proprietary analysis, with a majority of indicators flashing buy signals. The report details key technical metrics, including RSI, MACD, support/resistance levels, and moving average performance, to help assess the stock's short-term momentum and long-term trend.
SI-BONE Inc (SIBN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for SI-BONE Inc (SIBN), highlighting its business segments and regional contributions. As of June 17, SI-BONE Inc. had a market capitalization of $674.55 million. The company's revenue is primarily generated in the United States, accounting for 95.10% ($191.08M) of its total revenue, with international markets contributing 4.90% ($9.85M).
SI-BONE Inc (SIBN) Earnings Forecast: Future EPS & Revenue Growth Estimates
SI-BONE Inc (SIBN) currently has an earnings forecast score of 8.44 and an average price target of $25.00 from analysts, with a high of $32.00 and a low of $21.00. The consensus among 9 analysts is a "Buy" rating for the stock. The company's expected revenue for the next quarter is $55.26 million, and its EPS for the next quarter is anticipated to be -$0.15.
Precision Trading with Si-bone Inc. (SIBN) Risk Zones
This article provides a quantitative risk analysis for Si-bone Inc. (SIBN), highlighting a mid-channel oscillation pattern and a favorable 69.3:1 risk-reward setup. It outlines three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones for different risk profiles. The analysis also includes a multi-timeframe signal breakdown (Near-term, Mid-term, Long-term) to guide traders.
Precision Trading with Si-bone Inc. (SIBN) Risk Zones
This article provides a detailed analysis of Si-bone Inc. (SIBN) stock, highlighting a 69.3:1 risk-reward setup targeting a 19.2% gain. It outlines three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, along with multi-timeframe signal analysis. The report indicates mixed sentiment and choppy conditions ahead for SIBN.
SI-BONE Inc (SIBN) Shareholder Structure: Major Shareholders & Institutional Holdings
This article provides a detailed breakdown of SI-BONE Inc's (SIBN) shareholder structure, listing major shareholders by proportion and categorizing shareholder types. It also includes institutional shareholding trends over several quarters and recent shareholder activity, along with related ETF holdings.
SI-BONE Shareholders Endorse Governance and Lease Amendment
At SI-BONE's annual meeting in 2026, approximately 88% of stockholders participated, electing directors, ratifying PricewaterhouseCoopers LLP as their accounting firm, and approving executive compensation. The company also announced a Third Amendment to its lease, reinforcing operational commitments. These actions collectively demonstrate strong shareholder support for SI-BONE's current strategic and governance direction.
SI-BONE extends headquarters lease and reports annual meeting voting results By Investing.com
SI-BONE, Inc. (NASDAQ:SIBN) announced the extension of its headquarters lease for one month, with an option for an additional month, and reported the results of its annual stockholders' meeting. Shareholders re-elected two directors, ratified the appointment of their independent accounting firm, and approved executive compensation. The company also recently reported strong Q1 2026 financial results, exceeding EPS forecasts and raising revenue guidance.
Si-Bone director Jeffrey Dunn sells $54.5k in stock
SI-BONE, Inc. director Jeffrey W. Dunn sold 3,575 shares of company stock worth $54,505 on June 5, 2026, to cover tax obligations related to restricted stock unit vesting. Prior to this, on June 4, 2026, Dunn acquired 10,957 shares from vested restricted stock units. Following these transactions, Dunn directly holds 16,057 shares and indirectly holds 81,073 shares through a trust.
Si-Bone director Jeffrey Dunn sells $54.5k in stock
Jeffrey W. Dunn, a director at SI-BONE, Inc. (NASDAQ:SIBN), sold 3,575 shares of the company’s common stock for $54,505 on June 5, 2026. This sale was made to cover tax withholding obligations from restricted stock units and did not represent a discretionary trade. Following the transaction, Mr. Dunn directly holds 16,057 shares and indirectly holds 81,073 shares through a trust.
Director at SI-BONE (SIBN) granted 10,957 restricted stock units
SI-BONE, Inc. director Jeryl L. Hilleman was granted 10,957 restricted stock units (RSUs) as director compensation, which will vest 100% on the earlier of the company’s next annual general meeting or one year from the vesting commencement date, contingent on continued board service. These RSUs were granted at $0.00 per share and are not an open-market purchase. Following this award, Hilleman's direct holdings now total 43,772 shares of common stock, including the unvested units.
SI-BONE extends headquarters lease and reports annual meeting voting results
SI-BONE, Inc. has announced a one-month extension of its headquarters lease in Santa Clara, California, with an option for an additional month. Concurrently, the company reported the results of its annual stockholders' meeting, where directors Jeffrey W. Dunn and John G. Freund, M.D. were elected, the appointment of PricewaterhouseCoopers LLP as its independent accounting firm was ratified, and executive compensation received advisory approval. The medical device company also recently reported stronger-than-expected Q1 2026 financial results, raising its revenue and gross margin guidance.
[8-K] SI-BONE, Inc. Reports Material Event
SI-BONE, Inc. filed an 8-K report detailing two key events. First, the company extended its headquarters office lease for one month, with an option for an additional month, for their Santa Clara location. Second, the company held its Annual Meeting of Stockholders where directors were elected, PricewaterhouseCoopers LLP was ratified as the independent auditor, and executive compensation was approved on an advisory basis.
SI-BONE extends headquarters lease and reports annual meeting voting results
SI-BONE, Inc. has extended its headquarters lease for one month, with an option for an additional month, for its Santa Clara, California office. The company also announced the results of its annual meeting, where shareholders elected two directors, ratified the appointment of its independent accounting firm, and approved executive compensation. These developments follow a recent financial report where SI-BONE exceeded EPS forecasts but slightly missed revenue, subsequently raising guidance.
SI-BONE (SIBN) director granted 10,957 RSUs in new equity award
SI-BONE, Inc. director Mika Nishimura was granted 10,957 restricted stock units (RSUs) of common stock at no cash cost. These RSUs will vest 100% upon the earlier of the next annual stockholder meeting or one year from the vesting start date, provided she remains on the Board. Following this award, Nishimura directly holds a total of 43,673 shares, including these unvested units.
SI-BONE (SIBN) director granted 10,957 restricted stock units and reports holdings
SI-BONE, Inc. director John Gordon Freund was granted 10,957 restricted stock units (RSUs) at $0.00 per share as compensation. These RSUs will vest 100% on the earlier of the next annual general meeting or one year from the vesting commencement date, contingent on his continued board service. Following this grant, Freund directly holds 54,258 shares and is associated with 91,767 shares held indirectly through a family partnership.
Si-Bone director Jeffrey Dunn sells $54.5k in stock
SI-BONE director Jeffrey W. Dunn sold 3,575 shares for $54,505 to cover tax obligations related to vested restricted stock units (RSUs). This sale followed his acquisition of 10,957 shares from RSU settlements. After these transactions, Dunn directly holds 16,057 shares and indirectly holds 81,073 shares through a trust.
SI-BONE (SIBN) director receives 10,957-share restricted stock grant
SI-BONE, Inc. director Thomas A. West was granted 10,957 shares of common stock in the form of restricted stock units at no cash cost. Following this award, his direct holdings total 37,947 shares, including previously granted RSUs. The new RSUs will vest 100% upon the earlier of the company's next annual general meeting or one year from the vesting commencement date, conditional on his continuous service on the Board.
SI-BONE (SIBN) director awarded 10,957 RSUs, total holdings 76,679 shares
SI-BONE, Inc. director Timothy E. Davis Jr. was awarded 10,957 restricted stock units (RSUs) in a recent transaction, bringing his total direct holdings to 76,679 shares, including these new RSUs. These RSUs, which represent a contingent right to receive one share of common stock each, will vest 100% on the earlier of the next annual general meeting or one year from the vesting commencement date, contingent on his continued service on the board. The transaction was reported in a Form 4 filing, indicating an equity-based compensation grant with a reported price of $0.00 per share.
Technical Reactions to SIBN Trends in Macro Strategies
This article analyzes Si-bone Inc. (NASDAQ: SIBN) using AI models, identifying a positive near-term sentiment while broader alignment remains weak, characterized by a mid-channel oscillation pattern. It presents three distinct trading strategies (Position, Momentum Breakout, Risk Hedging) tailored to different risk profiles, along with multi-timeframe signal analysis and specific entry, target, and stop-loss levels for SIBN.
SI-BONE To Present at Truist Securities 2026 MedTech Conference on June 16, 2026
SI-BONE, Inc. announced its participation in the 2026 Truist Securities MedTech Conference in Boston, MA. The company, a leader in procedural solutions for compromised bone, will host a fireside chat on June 16, 2026. Investors can register to listen to the webcast, which will also be archived on SI-BONE's website.
SI-BONE To Present at Truist Securities 2026 MedTech Conference on June 16, 2026
SI-BONE, Inc. (Nasdaq: SIBN) announced its participation in the 2026 Truist Securities MedTech Conference in Boston, MA. The company's management will host a fireside chat on June 16, 2026, at 5:40 a.m. PT/8:40 a.m. ET. Investors can register to listen to the conference call via webcast on the company's website.
SI-BONE To Present at Truist Securities 2026 MedTech Conference on June 16, 2026
SI-BONE, Inc. (Nasdaq: SIBN) announced its participation in the 2026 Truist Securities MedTech Conference in Boston, MA. Management will host a fireside chat on June 16, 2026, at 5:40 a.m. Pacific Time/ 8:40 a.m. Eastern Time. Interested investors can register to listen to the webcast via the company's website.
SI-BONE To Present at Truist Securities 2026 MedTech Conference on June 16, 2026
SI-BONE, Inc. (Nasdaq: SIBN) announced its participation in the 2026 Truist Securities MedTech Conference in Boston, MA. Management will host a fireside chat on June 16, 2026, at 5:40 a.m. Pacific Time/8:40 a.m. Eastern Time. Investors can register for the live webcast or access the archived replay on the company's website.
Medtech firm SI-BONE plans Truist fireside chat June 16
SI-BONE (Nasdaq:SIBN) announced its participation in the 2026 Truist Securities MedTech Conference in Boston, MA. Management will host a fireside chat on June 16, 2026, at 5:40 a.m. PT / 8:40 a.m. ET. A live audio webcast and a 90-day replay will be available on the company's investor website for interested investors.
Si-Bone director Davis Jr sells $104k in common stock
SI-BONE, Inc. director Timothy E. Davis Jr. sold $104,186 worth of common stock in late May after exercising stock options. The sales occurred at prices between $14.12 and $14.505 per share. Despite the insider sale, analysts view SI-BONE as undervalued, with price targets ranging from $18 to $32, and the company recently reported strong Q1 2026 financial results with revenue growth and a narrower net loss than expected.
Si-Bone director Davis Jr sells $104k in common stock
SI-BONE director, Timothy E. Davis Jr., sold common stock worth $104,186 over two days in late May, following the exercise of stock options. These sales occurred at prices between $14.12 and $14.505 per share. The company's stock is currently trading near its 52-week low but is considered undervalued by analysts, with price targets set much higher.
Si-Bone director Davis Jr sells $104k in common stock
Timothy E. Davis Jr., a director at SI-BONE, Inc. (NASDAQ:SIBN), sold over $104,000 worth of common stock in late May 2026, following the exercise of stock options. These sales occurred as SI-BONE shares were trading near the lower end of their 52-week range, despite analysts' price targets suggesting undervaluation. The company recently reported strong first-quarter 2026 financial results with narrower losses and increased revenue guidance, supported by a strong cash position.
SI-BONE (SIBN) director exercises options and sells common shares
SI-BONE, Inc. director Timothy E. Davis Jr. exercised options for 12,064 shares of common stock at $4.32 per share on May 28, 2026, and subsequently sold a total of 7,280 shares (3,780 at $14.4706 and 3,500 at $14.1394) on May 28 and 29, 2026. Following these transactions, he directly holds 65,722 shares, which includes 8,675 shares related to restricted stock units. The filing indicates a moderate impact with a negative sentiment due to the net selling activity by the insider.
Wall Street analysts predict a 71.13% upside in Si-Bone (SIBN): Here's what you should know
This article mentions that Wall Street analysts are predicting a significant 71.13% upside for Si-Bone (SIBN) stock. However, the provided content is incomplete, and therefore, no further details or insights into this prediction can be extracted.
